Omholt, Stig W.
Lejneva, Raissa
Donate, Maria Jose Lagartos
Caponio, Domenica
Fang, Evandro Fei
Kobro-Flatmoen, Asgeir
Funding for this research was provided by:
Olav Thon Stiftelsen
Norges Forskningsråd
Cure Alzheimer’s Fund (282952, 282952, 282952)
Helse Sør-Øst RHF
Molecule AG/VITADAO (282942, 282942, 282942)
NordForsk Foundation (119986, 119986, 119986)
National Natural Science Foundation of China (81971327, 81971327, 81971327)
Akershus University Hospital
Civitan Norges Forskningsfond (281931, 281931, 281931)
Czech Republic-Norway KAPPA programme (TO01000215, TO01000215, TO01000215)
NTNU Norwegian University of Science and Technology
Article History
Received: 8 January 2024
Accepted: 3 June 2024
First Online: 25 June 2024
Declarations
:
: E.F.F. is the co-owner of Fang-S Consultation AS (Organization number 931 410 717); he has an MTA with LMITO Therapeutics Inc (South Korea), a CRADA arrangement with ChromaDex (USA), a commercialization agreement with Molecule AG/VITADAO; he is a consultant to Aladdin Healthcare Technologies (UK and Germany), the Vancouver Dementia Prevention Centre (Canada), Intellectual Labs (Norway), MindRank AI (China), and NYO3 (Norway and China).
: All procedures were approved by the Norwegian Animal Research Authority, and follow the European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes. The Regional Committees for Medical and Health Research Ethics, Norway (permit 82685) approved the use of archival postmortem human brain sections.
: All authors consent to publication of this manuscript.